Ondine Biomedical Inc. Appointment of Nominated and Financial Adviser
03 February 2025 - 6:00PM
RNS Regulatory News
RNS Number : 5591V
Ondine Biomedical Inc.
03 February 2025
3 February 2025
ONDINE BIOMEDICAL
INC.
("Ondine
Biomedical", "Ondine", or the "Company")
Appointment of Nominated and
Financial Adviser
Ondine Biomedical Inc. (LON:
OBI), a Canadian life sciences company pioneering light-activated
antimicrobial treatments, is pleased to announce the appointment of
Strand Hanson Limited as the Company's Nominated and Financial
Adviser, with immediate effect. The Company's existing broker, RBC
Capital Markets, will assume the role of sole Broker with immediate
effect.
Enquiries:
|
Ondine Biomedical
Inc.
|
www.ondinebio.com
|
|
Carolyn Cross, CEO
|
Via Vane
Percy & Roberts
|
|
Strand Hanson Limited (Nominated & Financial
Adviser)
|
|
|
James Harris, Richard
Johnson
|
+44 (0)20
7409 3494
|
|
|
|
|
RBC
Capital Markets (Broker)
|
|
|
Rupert Walford, Kathryn
Deegan
|
+44 (0)20
7653 4000
|
|
|
|
|
Vane Percy & Roberts (Media Contact)
|
|
|
Simon Vane Percy, Amanda
Bernard
|
+44 (0)77
1000 5910
|
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian
life sciences company and leader in light-activated antimicrobial
therapies (also known as 'photodisinfection'). Ondine has a
pipeline of investigational products, based on its proprietary
photodisinfection technology, in various stages of
development.
Ondine's nasal photodisinfection
system has a CE mark in Europe and is approved in Canada and
several other countries under the name Steriwave®. In
the US, it has been granted Qualified Infectious Disease Product
designation and Fast Track status by the FDA and is currently
undergoing clinical trials for regulatory approval. Products beyond
nasal photodisinfection include therapies for a variety of medical
indications such as chronic sinusitis, ventilator-associated
pneumonia, burns and other indications.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
APPSSWFWEEISESE
Ondine Biomedical (LSE:OBI)
Historical Stock Chart
From Jan 2025 to Feb 2025
Ondine Biomedical (LSE:OBI)
Historical Stock Chart
From Feb 2024 to Feb 2025
